Department of Otorhinolaryngology, Katip Celebi University Ataturk Teaching and Research Hospital, Izmir, Turkey.
Department of Pathology, Katip Celebi University Ataturk Teaching and Research Hospital, Izmir, Turkey.
Am J Otolaryngol. 2022 Jul-Aug;43(4):103477. doi: 10.1016/j.amjoto.2022.103477. Epub 2022 May 4.
This study aimed to examine the relationship between checkpoint receptors (PD-1, PD-L1, PD-L2, CTLA-4) and lymphoid infiltration level (TILs) with prognostic features of patients with laryngeal squamous cell carcinoma (LSCC).
A retrospective study was designed at a tertiary referential university hospital between April 2008 and December 2020. The surgical specimen of the patients who met the eligibility criteria were re-examined histopathological, sociodemographic, clinical, pathological, and follow-up findings of patients were determined. The impact of PD-1, PD-L1, PD-L2, CTLA4, and TILs levels for the presence of cancer recurrence, disease-specific mortality, overall survival (OS), disease-free survival (DFS) was investigated.
Forty-five patients with LSCC were included in the study. The mean follow-up period was 48.3 ± 14.3 months (min: 36, max 84). TILs scores were detected significantly lower in patients with distant metastasis and recurrence (p = 0.046 and 0.010). Also, only TILs was a significant risk factor for recurrence and survival among the PD-1, PD-L1, PD-L2, CTLA-4, and TILs (HR = 0.217 CI: 0.070-0.679, p = 0.009 and HR = 0.566, CI: 0,321-980, p = 0.048). Similarly, for the TILs score: > 1 was significant for DFS. (Long-Rank = 0.009). The examined markers and TILs scores were not a significant predictive factor for OS.
An increase in TILs density in LSCCs is associated with a better prognosis. However, PD-1, PD-L1, PD-L2, CTLA-4 could not be associated with prognosis. Controlled studies combined with immunotherapy treatment results are needed to reveal their role as a marker and prognostic factor of the anti-tumor immune response.
本研究旨在探讨检查点受体（PD-1、PD-L1、PD-L2、CTLA-4）与淋巴浸润水平（TILs）与喉鳞状细胞癌（LSCC）患者预后特征的关系。
本研究为 2008 年 4 月至 2020 年 12 月在一家三级转诊大学医院进行的回顾性研究。对符合入选标准的患者的手术标本进行重新检查，确定患者的组织病理学、社会人口学、临床、病理和随访发现。研究了 PD-1、PD-L1、PD-L2、CTLA4 和 TILs 水平对癌症复发、疾病特异性死亡率、总生存期（OS）、无病生存期（DFS）的影响。
本研究共纳入 45 例 LSCC 患者。平均随访时间为 48.3±14.3 个月（最短：36 个月，最长 84 个月）。在远处转移和复发的患者中，TILs 评分明显较低（p=0.046 和 0.010）。此外，在 PD-1、PD-L1、PD-L2、CTLA-4 和 TILs 中，只有 TILs 是复发和生存的显著危险因素（HR=0.217 CI：0.070-0.679，p=0.009 和 HR=0.566，CI：0.321-0.980，p=0.048）。同样，对于 TILs 评分：>1 与 DFS 显著相关（Long-Rank=0.009）。检查标志物和 TILs 评分不是 OS 的显著预测因子。
LSCC 中 TILs 密度的增加与预后较好相关。然而，PD-1、PD-L1、PD-L2、CTLA-4 不能与预后相关。需要结合免疫治疗结果的对照研究来揭示它们作为抗肿瘤免疫反应的标志物和预后因素的作用。
